Novavax 是哪一种 protein vaccine？ Protein nanoparticle vaccine Soluble protein vaccine Virus-like particle vaccine Jxnc 发表于 2022-02-16 17:04
novavax: recombinant nanoparticle vaccine technology 高端： This vaccine is made by the recombinant S-2P spike protein.[3] It is adjuvanted with CpG 1018 supplied by Dynavax, which was used in a previously FDA-approved adult hepatitis B vaccine
对delta和omicron哪来的数据？ The study, led by Novavax researchers in Gaithersburg, Maryland, involved 29,949 adults who received the Novavax vaccine at 113 sites in the United States and 6 in Mexico from Dec 27, 2020, to Feb 18, 2021, before the emergence of the highly transmissible Delta (B1617.2) and Omicron (B.1.1.529) variants. Participants were followed until Apr 19, 2021. 他家一直没法上市，没有什么实验空间，不能像辉瑞和摩德纳那样各种数据信手拈来
目前做了大孩子的，12-17 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, achieved its primary effectiveness endpoint in the pediatric expansion of its PREVENT-19 pivotal Phase 3 trial and demonstrated 80% efficacy overall at a time when the Delta variant was the predominant circulating strain in the U.S. The study enrolled 2,247 adolescents aged 12 through 17-years across 73 sites in the U.S. to evaluate safety, effectiveness (immunogenicity), and efficacy, with an emphasis on ensuring well balanced racial and ethnic representation among participants.
太卑鄙了
是的，我很多朋友等这个。
你从哪里看出来的Novavax 不行的？
我怎么觉得是FDA故意拖延。辉瑞疫苗5岁以下三期失败，FDA还要药厂硬上。最后时刻结果太差，只好等第三针的数据。
好事儿啊，鼓励你们都去打做Guinea pig，给吃瓜群众多多提供runtime data。
这个不存在Guinea pig。因为是传统技术，其他使用同样技术的疫苗已经证明了安全性。
别的国家都通过了，等我们打已经有很多数据出来了。
哪里有数据？
你是拍脑袋想出来的吧。
对原毒株，Alpha，Delta，Novavax两针的防护率和辉瑞，Moderna差不多。 Booster, 在英国的mix and match，Novavax稍逊于Moderna， 比辉瑞好不少，排第二。 对Omicron变种，Novavax是目前所有疫苗中最好的。
Sorry, 那我撤回我说的话，确实是拍脑袋想出来的，我Omicron这波看到几个参加novavax trial打了三针还感染的病人，病程也不轻。sorry, bias了，毕竟三针mRNA感染的几率也够高的，主要是o的免疫逃逸太厉害。
Novavax对Omicron防护率也下降，但相比辉瑞和Moderna要好一些。
而美国FDA要求预审30天，从12月31日到1月31日，然后允许Novavax提交正式的EUA申请。按理FDA应该已经审核完了，但过去2周半了，还没有安排 advisory panel 会议（需要提前2－3周安排）。
而辉瑞和Moderna是上交EUA申请后几天－2周内就安排了，所以给人的感觉FDA就是在拖延。
如果真是这么好没有理由一直拖到最近才申请，这可是美国本土的公司。要是效果拔群政府没有理由不推广这个。毕竟传统疫苗可以打消很多人对安全的顾虑。要不是他们有重组蛋白疫苗的通病，要不就是生产方面问题。
辉瑞和莫得纳申请EUA的时候没有别的疫苗可打自然审批得快，现在绝大多数人都打过了也不缺疫苗没有迫切性了。美国剩下没打疫苗的人里面绝大多数也不会因为这个疫苗批准就去打的。
谢谢你们愿意先打的勇气，那就放心去打吧。
https://tw.news.yahoo.com/bnt-%E9%AB%98%E7%AB%AF%E7%96%AB%E8%8B%97%E5%89%AF%E4%BD%9C%E7%94%A8%E8%A9%95%E6%AF%94-%E5%BF%83%E8%82%8C%E7%82%8E%E6%80%95%E6%80%95-%E9%86%AB%E5%BB%BA%E8%AD%B0-%E9%80%99%E9%A1%9E%E4%BA%BA-071554186.html
免疫科醫師林恆圭也直言，不管哪個廠牌，多少都有這些副作用，但從比例上來講，高端疫苗較低。 至於死亡率部分，也是高端最低。截至8月24日指揮中心統計，AZ接種644萬劑，莫德納367萬劑，高端28萬劑。 施打AZ後死亡者有540人（死亡率約為0.0084%）；施打莫德納後死亡者119人（死亡率約為0.0032%）；施打高端後死亡4人（死亡率約0.0014%）。
谢谢，我自己去做些功课，又对这个疫苗有些信心了
Protein nanoparticle vaccine Soluble protein vaccine Virus-like particle vaccine
这么看高端非常好啊，对novavax有期待。
高端是用novavax技术？
高端没有用树皮佐剂啊
novavax: recombinant nanoparticle vaccine technology
高端： This vaccine is made by the recombinant S-2P spike protein.[3] It is adjuvanted with CpG 1018 supplied by Dynavax, which was used in a previously FDA-approved adult hepatitis B vaccine
对delta和omicron哪来的数据？
The study, led by Novavax researchers in Gaithersburg, Maryland, involved 29,949 adults who received the Novavax vaccine at 113 sites in the United States and 6 in Mexico from Dec 27, 2020, to Feb 18, 2021, before the emergence of the highly transmissible Delta (B1617.2) and Omicron (B.1.1.529) variants. Participants were followed until Apr 19, 2021.
他家一直没法上市，没有什么实验空间，不能像辉瑞和摩德纳那样各种数据信手拈来
很多没打的如果面临雇主强制打，那当然可以选择这个去打
疫苗booster估价6个月以后也开始慢慢衰减了吧，到时候nvax通过了就打nvax的，以后每年有需要打肯定首选副作用小的疫苗啊，pfizer/mrna组合的刚打完几天还是挺难过的，有其他选择的真的不想再试这两家的了
等得花儿都谢了
哪些副作用？
是吗
FDA对辉瑞，莫代耐，审查大放水，我跑去打两针，后悔的无穷无尽。
FDA 对强生疫苗也是审查大放水，现在没人打，只能政府买下捐给非洲。
默克的covid19 的药也是，有效率30%，副作用一大堆。拜登政府买了很多，是不是又要捐出去了?
期待
期待booster用它家
目前做了大孩子的，12-17
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, achieved its primary effectiveness endpoint in the pediatric expansion of its PREVENT-19 pivotal Phase 3 trial and demonstrated 80% efficacy overall at a time when the Delta variant was the predominant circulating strain in the U.S. The study enrolled 2,247 adolescents aged 12 through 17-years across 73 sites in the U.S. to evaluate safety, effectiveness (immunogenicity), and efficacy, with an emphasis on ensuring well balanced racial and ethnic representation among participants.
悬